Homocysteine Testing
Defines coverage stance for measurement of plasma homocysteine for cardiovascular disease (CVD), venous thromboembolism (VTE), and other diagnoses, including medically necessary indications (homocystinuria, recurrent pregnancy loss, borderline B12 deficiency) and investigational/experimental determinations for screening/evaluation/management of CVD and VTE.
Merged two prior homocysteine policies into a single Homocysteine Testing policy.
Added medically necessary non-cardiac indications: recurrent pregnancy loss and venous thromboembolism.
Clarified that homocysteine testing is experimental/investigational for any diagnosis other than homocystinuria, recurrent pregnancy loss, borderline vitamin B12 deficiency, or venous thromboembolism.
Multiple updates to coding: ICD-10 codes were added and later removed in revisions; various ICD-9/ICD-10 code lists were edited across revision history.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.